30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Dianthus Therapeutics Inc (DNTH)

Track

Over the last 90 days, Dianthus Therapeutics Inc. has seen significant insider selling activity, totaling over $29.4 million. Notably, EVP, Head of R&D Simrat Randhawa and EVP, CFO & CBO Ryan Savitz have executed multiple planned and proposed sales. There have been no reported insider purchases during this period. The stock has experienced a slight decline of 1.4% over the past 90 days.
Stock chart
Ticker: DNTH Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Veness Adam M
SVP, General Counsel and Sec.
2 sales — total 200,000 USD
Planned sale 17 Jun 2026
Value US$1,103,419.92 | Price 265.98 | Shares 22,661
Planned sale 17 Jun 2026
Value US$2,626,910.56 | Price 64.45 | Shares 75,718
Proposed sale 17 Jun 2026
Value US$4,711,326.63 | Price 185.95 | Shares 32,244
Planned sale 1 Jun 2026
Value US$380,007.83 | Price 91.37 | Shares 4,159
Planned sale 1 Jun 2026
Value US$1,537,068.96 | Price 90.72 | Shares 16,943
Planned sale 1 Jun 2026
Value US$487,000.16 | Price 89.72 | Shares 5,428
Proposed sale 1 Jun 2026
Value US$2,467,555.30 | Price 93.01 | Shares 26,530
Planned sale 8 May 2026
Value US$51,196.53 | Price 85.47 | Shares 599
Planned sale 9 Apr 2026
Value US$738,844.16 | Price 89.84 | Shares 8,224
Proposed sale 9 Apr 2026
Value US$719,435.52 | Price 87.48 | Shares 8,224
Planned sale 31 Mar 2026
Value US$618,625.28 | Price 85.54 | Shares 7,232
Planned sale 31 Mar 2026
Value US$1,646,493.33 | Price 84.57 | Shares 19,469
Planned sale 31 Mar 2026
Value US$5,017,220.00 | Price 83.90 | Shares 59,800
Planned sale 31 Mar 2026
Value US$195,999.44 | Price 82.84 | Shares 2,366
Planned sale 31 Mar 2026
Value US$65,088.00 | Price 81.36 | Shares 800
Planned sale 31 Mar 2026
Value US$119,171.25 | Price 80.25 | Shares 1,485
Planned sale 31 Mar 2026
Value US$1,721,119.50 | Price 78.86 | Shares 21,825
Planned sale 31 Mar 2026
Value US$108,878.70 | Price 78.33 | Shares 1,390
Planned sale 31 Mar 2026
Value US$47,985.89 | Price 80.11 | Shares 599
Proposed sale 31 Mar 2026
Value US$9,086,458.15 | Price 79.45 | Shares 114,367
Proposed sale 31 Mar 2026
Value US$95,181.10 | Price 79.45 | Shares 1,198
Planned sale 24 Mar 2026
Value US$2,153,711.70 | Price 78.05 | Shares 27,594
Proposed sale 24 Mar 2026
Value US$2,188,756.08 | Price 79.32 | Shares 27,594
Planned sale 12 Mar 2026
Value US$25,659.00 | Price 85.53 | Shares 300
Planned sale 12 Mar 2026
Value US$16,676.00 | Price 83.38 | Shares 200
Planned sale 12 Mar 2026
Value US$319,480.90 | Price 82.66 | Shares 3,865
Planned sale 12 Mar 2026
Value US$1,918,263.75 | Price 81.75 | Shares 23,465
Planned sale 12 Mar 2026
Value US$1,279,414.92 | Price 80.71 | Shares 15,852
Planned sale 12 Mar 2026
Value US$76,977.00 | Price 85.53 | Shares 900
Planned sale 12 Mar 2026
Value US$16,676.00 | Price 83.38 | Shares 200
Planned sale 12 Mar 2026
Value US$1,056,949.60 | Price 82.60 | Shares 12,796
Planned sale 12 Mar 2026
Value US$5,355,359.58 | Price 81.74 | Shares 65,517
Planned sale 12 Mar 2026
Value US$3,510,418.45 | Price 80.69 | Shares 43,505
Planned sale 12 Mar 2026
Value US$2,756,468.40 | Price 81.48 | Shares 33,830
Proposed sale 12 Mar 2026
Value US$2,903,967.20 | Price 85.84 | Shares 33,830
Proposed sale 12 Mar 2026
Value US$3,749,662.88 | Price 85.84 | Shares 43,682
Proposed sale 12 Mar 2026
Value US$10,551,281.12 | Price 85.84 | Shares 122,918
Planned sale 4 Dec 2025
Value US$903,600.00 | Price 45.18 | Shares 20,000
Proposed sale 4 Dec 2025
Value US$879,400.00 | Price 43.97 | Shares 20,000
Planned sale 14 Nov 2025
Value US$4,158,442.34 | Price 38.14 | Shares 109,031
Planned sale 13 Nov 2025
Value US$700,686.72 | Price 37.72 | Shares 18,576
Planned sale 13 Nov 2025
Value US$1,584,015.60 | Price 37.04 | Shares 42,765
Planned sale 13 Nov 2025
Value US$936,742.80 | Price 35.80 | Shares 26,166
Proposed sale 13 Nov 2025
Value US$7,609,951.36 | Price 38.72 | Shares 196,538
Planned sale 9 Sep 2025
Value US$700,000.00 | Price 35.00 | Shares 20,000
Proposed sale 9 Sep 2025
Value US$636,000.00 | Price 31.80 | Shares 20,000
Buy 29 Sep 2023
Value US$336,252.10 | Price 13.63 | Shares 24,670
Buy 26 Sep 2023
Value US$394,500.00 | Price 13.15 | Shares 30,000
Buy 22 Sep 2023
Value US$26,400.00 | Price 13.20 | Shares 2,000
Buy 21 Sep 2023
Value US$26,400.00 | Price 13.20 | Shares 2,000
Buy 19 Sep 2023
Value US$396,000.00 | Price 13.20 | Shares 30,000
Buy 13 Sep 2023
Value US$110,155.92 | Price 11.76 | Shares 9,367
Buy 12 Sep 2023
Value US$161,523.95 | Price 10.85 | Shares 14,887
Sale 8 Feb 2023
Value US$1,230,000.00 | Price 0.82 | Shares 1,500,000
Sale 7 Feb 2023
Value US$1,826,000.00 | Price 0.83 | Shares 2,200,000
Buy 29 Jun 2020
Value US$10,000,000.00 | Price 8.00 | Shares 1,250,000
Planned sale 10 Jan 2020
Value US$170,800.00 | Price 15.25 | Shares 11,200
Planned sale 2 Jan 2020
Value US$42,280.00 | Price 15.10 | Shares 2,800
Planned sale 2 Jan 2020
Value US$169,816.58 | Price 15.04 | Shares 11,294
Planned sale 24 Dec 2019
Value US$71,452.63 | Price 16.01 | Shares 4,463
Planned sale 24 Dec 2019
Value US$126,432.00 | Price 16.00 | Shares 7,902
Planned sale 23 Dec 2019
Value US$67,021.43 | Price 16.03 | Shares 4,181
Planned sale 23 Dec 2019
Value US$158,168.01 | Price 16.03 | Shares 9,867
Planned sale 23 Dec 2019
Value US$43,754.55 | Price 15.10 | Shares 2,897
Planned sale 20 Dec 2019
Value US$1,162,616.57 | Price 15.16 | Shares 76,711
Planned sale 20 Dec 2019
Value US$13,785.00 | Price 15.00 | Shares 919
Planned sale 10 Dec 2019
Value US$66,319.20 | Price 15.10 | Shares 4,392
Planned sale 10 Dec 2019
Value US$255,825.00 | Price 15.00 | Shares 17,055
Planned sale 9 Dec 2019
Value US$69,210.00 | Price 15.00 | Shares 4,614
Sale 2 Dec 2019
Value US$33,036.00 | Price 13.21 | Shares 2,500
Sale 2 Dec 2019
Value US$18,279.30 | Price 13.31 | Shares 1,373
Sale 2 Dec 2019
Value US$46,204.72 | Price 12.74 | Shares 3,627
Sale 20 Nov 2019
Value US$60,000.00 | Price 12.00 | Shares 5,000
Sale 1 Nov 2019
Value US$53,333.50 | Price 10.67 | Shares 5,000
Sale 1 Oct 2019
Value US$50,064.00 | Price 10.01 | Shares 5,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-18 2026-06-17 PlS Planned sale
Veness Adam M

SVP, General Counsel and Sec.

Officer
22,661 +10.5%
265.98
US$1,103,420 		22,661 +10.5% 265.98 US$1,103,420
2026-06-18 2026-06-17 PlS Planned sale
Veness Adam M

SVP, General Counsel and Sec.

Officer
75,718 +11.4%
64.45
US$2,626,911 		75,718 +11.4% 64.45 US$2,626,911
2026-06-17 2026-06-17 PrS Proposed sale
ADAM M VENESS

Officer

Officer
32,244
185.95
US$4,711,327 		32,244 185.95 US$4,711,327
2026-06-02 2026-06-01 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
4,159 -51.0%
91.37
US$380,008 		4,159 -51.0% 91.37 US$380,008
2026-06-02 2026-06-01 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
16,943 -67.5%
90.72
US$1,537,069 		16,943 -67.5% 90.72 US$1,537,069
2026-06-02 2026-06-01 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
5,428 -17.8%
89.72
US$487,000 		5,428 -17.8% 89.72 US$487,000
2026-06-01 2026-06-01 PrS Proposed sale
1.4
SIMRAT RANDHAWA

Officer

Officer
26,530
93.01
US$2,467,555 		26,530 93.01 US$2,467,555
2026-05-11 2026-05-08 PlS Planned sale
2.8
Soteropoulos Paula
Non-Executive Director
599 -100.0%
85.47
US$51,197 		599 -100.0% 85.47 US$51,197
2026-04-10 2026-04-09 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
8,224 -100.0%
89.84
US$738,844 		8,224 -100.0% 89.84 US$738,844
2026-04-09 2026-04-09 PrS Proposed sale
RYAN SAVITZ

Officer

Officer
8,224
87.48
US$719,436 		8,224 87.48 US$719,436
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
7,232 -100.0%
85.54
US$618,625 		7,232 -100.0% 85.54 US$618,625
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
19,469 -72.9%
84.57
US$1,646,493 		19,469 -72.9% 84.57 US$1,646,493
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
59,800 -69.1%
83.90
US$5,017,220 		59,800 -69.1% 83.90 US$5,017,220
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
2,366 -2.7%
82.84
US$195,999 		2,366 -2.7% 82.84 US$195,999
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
800 -0.9%
81.36
US$65,088 		800 -0.9% 81.36 US$65,088
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
1,485 -1.6%
80.25
US$119,171 		1,485 -1.6% 80.25 US$119,171
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
21,825 -19.3%
78.86
US$1,721,120 		21,825 -19.3% 78.86 US$1,721,120
2026-04-01 2026-03-31 PlS Planned sale
Savitz Ryan

EVP, CFO & CBO

Officer
1,390 -1.2%
78.33
US$108,879 		1,390 -1.2% 78.33 US$108,879
2026-04-01 2026-03-31 PlS Planned sale
2.8
Soteropoulos Paula
Non-Executive Director
599 -100.0%
80.11
US$47,986 		599 -100.0% 80.11 US$47,986
2026-03-31 2026-03-31 PrS Proposed sale
RYAN SAVITZ

Officer

Officer
114,367
79.45
US$9,086,458 		114,367 79.45 US$9,086,458
2026-03-31 2026-03-31 PrS Proposed sale
2.8
PAULA C SOTEROPOULOS

Director

Non-Executive Director
1,198
79.45
US$95,181 		1,198 79.45 US$95,181
2026-03-26 2026-03-24 PlS Planned sale
2.8
Soteropoulos Paula
Non-Executive Director
27,594 -100.0%
78.05
US$2,153,712 		27,594 -100.0% 78.05 US$2,153,712
2026-03-24 2026-03-24 PrS Proposed sale
2.8
PAULA C SOTEROPOULOS

Director

Non-Executive Director
27,594
79.32
US$2,188,756 		27,594 79.32 US$2,188,756
2026-03-13 2026-03-12 PlS Planned sale
0.5
CARR EDWARD

CHIEF ACCOUNTING OFFICER

Officer
300 -100.0%
85.53
US$25,659 		300 -100.0% 85.53 US$25,659
2026-03-13 2026-03-12 PlS Planned sale
0.5
CARR EDWARD

CHIEF ACCOUNTING OFFICER

Officer
200 -40.0%
83.38
US$16,676 		200 -40.0% 83.38 US$16,676
2026-03-13 2026-03-12 PlS Planned sale
0.5
CARR EDWARD

CHIEF ACCOUNTING OFFICER

Officer
3,865 -88.5%
82.66
US$319,481 		3,865 -88.5% 82.66 US$319,481
2026-03-13 2026-03-12 PlS Planned sale
0.5
CARR EDWARD

CHIEF ACCOUNTING OFFICER

Officer
23,465 -84.3%
81.75
US$1,918,264 		23,465 -84.3% 81.75 US$1,918,264
2026-03-13 2026-03-12 PlS Planned sale
0.5
CARR EDWARD

CHIEF ACCOUNTING OFFICER

Officer
15,852 -36.3%
80.71
US$1,279,415 		15,852 -36.3% 80.71 US$1,279,415
2026-03-13 2026-03-12 PlS Planned sale
Garcia Marino

CEO AND PRESIDENT

Executive Director
900 -100.0%
85.53
US$76,977 		900 -100.0% 85.53 US$76,977
2026-03-13 2026-03-12 PlS Planned sale
Garcia Marino

CEO AND PRESIDENT

Executive Director
200 -18.2%
83.38
US$16,676 		200 -18.2% 83.38 US$16,676
2026-03-13 2026-03-12 PlS Planned sale
Garcia Marino

CEO AND PRESIDENT

Executive Director
12,796 -92.1%
82.60
US$1,056,950 		12,796 -92.1% 82.60 US$1,056,950
2026-03-13 2026-03-12 PlS Planned sale
Garcia Marino

CEO AND PRESIDENT

Executive Director
65,517 -82.5%
81.74
US$5,355,360 		65,517 -82.5% 81.74 US$5,355,360
2026-03-13 2026-03-12 PlS Planned sale
Garcia Marino

CEO AND PRESIDENT

Executive Director
43,505 -35.4%
80.69
US$3,510,418 		43,505 -35.4% 80.69 US$3,510,418
2026-03-13 2026-03-12 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
33,830 -100.0%
81.48
US$2,756,468 		33,830 -100.0% 81.48 US$2,756,468
2026-03-12 2026-03-12 PrS Proposed sale
1.4
SIMRAT RANDHAWA

Officer

Officer
33,830
85.84
US$2,903,967 		33,830 85.84 US$2,903,967
2026-03-12 2026-03-12 PrS Proposed sale
0.5
EDWARD CARR

Officer

Officer
43,682
85.84
US$3,749,663 		43,682 85.84 US$3,749,663
2026-03-12 2026-03-12 PrS Proposed sale
MARINO GARCIA

Director; Officer

Executive Director
122,918
85.84
US$10,551,281 		122,918 85.84 US$10,551,281
2025-12-05 2025-12-04 PlS Planned sale
Savitz Ryan

CFO & CBO

Officer
20,000 -100.0%
45.18
US$903,600 		20,000 -100.0% 45.18 US$903,600
2025-12-04 2025-12-04 PrS Proposed sale
RYAN SAVITZ

Officer

Officer
20,000
43.97
US$879,400 		20,000 43.97 US$879,400
2025-11-14 2025-11-14 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
109,031 -96.5%
38.14
US$4,158,442 		109,031 -96.5% 38.14 US$4,158,442
2025-11-14 2025-11-13 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
18,576 -82.3%
37.72
US$700,687 		18,576 -82.3% 37.72 US$700,687
2025-11-14 2025-11-13 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
42,765 -65.4%
37.04
US$1,584,016 		42,765 -65.4% 37.04 US$1,584,016
2025-11-14 2025-11-13 PlS Planned sale
1.4
Randhawa Simrat

EVP, Head of R&D

Officer
26,166 -28.6%
35.80
US$936,743 		26,166 -28.6% 35.80 US$936,743
2025-11-13 2025-11-13 PrS Proposed sale
1.4
SIMRAT RANDHAWA

Officer

Officer
196,538
38.72
US$7,609,951 		196,538 38.72 US$7,609,951
2025-09-11 2025-09-09 PlS Planned sale
Savitz Ryan

CFO & CBO

Officer
20,000 -100.0%
35.00
US$700,000 		20,000 -100.0% 35.00 US$700,000
2025-09-09 2025-09-09 PrS Proposed sale
RYAN SAVITZ

Officer

Officer
20,000
31.80
US$636,000 		20,000 31.80 US$636,000
2023-10-03 2023-09-29 B Purchase
3.5
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
24,670 +1.3%
13.63
US$336,252 		24,670 +1.3% 13.63 US$336,252
2023-09-28 2023-09-26 B Purchase
3.5
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
30,000 +1.6%
13.15
US$394,500 		30,000 +1.6% 13.15 US$394,500
2023-09-25 2023-09-22 B Purchase
1.4
Randhawa Simrat

Chief Medical Officer

Officer
2,000 +100.0%
13.20
US$26,400 		2,000 +100.0% 13.20 US$26,400
2023-09-25 2023-09-21 B Purchase
1.4
Randhawa Simrat

Chief Medical Officer

Officer
2,000 +inf%
13.20
US$26,400 		2,000 +inf% 13.20 US$26,400
2023-09-21 2023-09-19 B Purchase
3.5
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
30,000 +1.6%
13.20
US$396,000 		30,000 +1.6% 13.20 US$396,000
2023-09-13 2023-09-13 B Purchase
3.5
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
9,367 +0.5%
11.76
US$110,156 		9,367 +0.5% 11.76 US$110,156
2023-09-13 2023-09-12 B Purchase
3.5
Fairmount Funds Management LLC
Non-Executive Director Large shareholder
14,887 +0.8%
10.85
US$161,524 		14,887 +0.8% 10.85 US$161,524
2023-02-09 2023-02-08 S Sale
3.3
Third Rock Ventures IV, L.P.
Large shareholder
1,500,000 -32.9%
0.82
US$1,230,000 		1,500,000 -32.9% 0.82 US$1,230,000
2023-02-09 2023-02-07 S Sale
3.3
Third Rock Ventures IV, L.P.
Large shareholder
2,200,000 -32.6%
0.83
US$1,826,000 		2,200,000 -32.6% 0.83 US$1,826,000
2020-07-01 2020-06-29 B Purchase
3.4
Booth Bruce
Non-Executive Director
1,250,000 +inf%
8.00
US$10,000,000 		1,250,000 +inf% 8.00 US$10,000,000
2020-01-10 2020-01-10 PlS Planned sale
3.0
GARDNER JASON

See Remarks
11,200 -4.3%
15.25
US$170,800 		11,200 -4.3% 15.25 US$170,800
2020-01-03 2020-01-02 PlS Planned sale
3.0
GARDNER JASON

See Remarks
2,800 -1.1%
15.10
US$42,280 		2,800 -1.1% 15.10 US$42,280
2020-01-03 2020-01-02 PlS Planned sale
DAVIS JOHN C. JR

Chief Medical Officer
11,294 -57.6%
15.04
US$169,817 		11,294 -57.6% 15.04 US$169,817
2019-12-26 2019-12-24 PlS Planned sale ISACSON CHRISTINA K.

Chief Business Officer
4,463 -5.1%
16.01
US$71,453 		4,463 -5.1% 16.01 US$71,453
2019-12-26 2019-12-24 PlS Planned sale ZDRAVESKI ZORAN

See Remarks
7,902 -5.8%
16.00
US$126,432 		7,902 -5.8% 16.00 US$126,432
2019-12-26 2019-12-23 PlS Planned sale ZDRAVESKI ZORAN

See Remarks
4,181 -3.0%
16.03
US$67,021 		4,181 -3.0% 16.03 US$67,021
2019-12-26 2019-12-23 PlS Planned sale ISACSON CHRISTINA K.

Chief Business Officer
9,867 -10.1%
16.03
US$158,168 		9,867 -10.1% 16.03 US$158,168
2019-12-23 2019-12-23 PlS Planned sale
3.0
GARDNER JASON

See Remarks
2,897 -1.1%
15.10
US$43,755 		2,897 -1.1% 15.10 US$43,755
2019-12-20 2019-12-20 PlS Planned sale
3.0
GARDNER JASON

See Remarks
76,711 -22.2%
15.16
US$1,162,617 		76,711 -22.2% 15.16 US$1,162,617
2019-12-20 2019-12-20 PlS Planned sale DAVIS JOHN C. JR

Chief Medical Officer
919 -10.0%
15.00
US$13,785 		919 -10.0% 15.00 US$13,785
2019-12-13 2019-12-10 PlS Planned sale
3.0
GARDNER JASON

See Remarks
4,392 -1.3%
15.10
US$66,319 		4,392 -1.3% 15.10 US$66,319
2019-12-11 2019-12-10 PlS Planned sale DAVIS JOHN C. JR

Chief Medical Officer
17,055 -67.3%
15.00
US$255,825 		17,055 -67.3% 15.00 US$255,825
2019-12-11 2019-12-09 PlS Planned sale DAVIS JOHN C. JR

Chief Medical Officer
4,614 -35.7%
15.00
US$69,210 		4,614 -35.7% 15.00 US$69,210
2019-12-02 2019-12-02 S Sale
2.4
COOKE MICHAEL P.

Chief Scientific Officer
2,500 -1.0%
13.21
US$33,036 		2,500 -1.0% 13.21 US$33,036
2019-12-02 2019-12-02 S Sale
2.4
COOKE MICHAEL P.

Chief Scientific Officer
1,373 -0.6%
13.31
US$18,279 		1,373 -0.6% 13.31 US$18,279
2019-12-02 2019-12-02 S Sale
2.4
COOKE MICHAEL P.

Chief Scientific Officer
3,627 -1.5%
12.74
US$46,205 		3,627 -1.5% 12.74 US$46,205
2019-11-25 2019-11-20 S Sale
2.4
COOKE MICHAEL P.

Chief Scientific Officer
5,000 -2.0%
12.00
US$60,000 		5,000 -2.0% 12.00 US$60,000
2019-11-01 2019-11-01 S Sale
1.0
COOKE MICHAEL P.

Chief Scientific Officer
5,000 -1.9%
10.67
US$53,334 		5,000 -1.9% 10.67 US$53,334
2019-10-03 2019-10-01 S Sale
1.0
COOKE MICHAEL P.

Chief Scientific Officer
5,000 -1.9%
10.01
US$50,064 		5,000 -1.9% 10.01 US$50,064
Explore more

More insider trading research around Dianthus Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America